| Followers | 59 |
| Posts | 7593 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Thursday, September 28, 2023 7:48:12 PM
Monk44, What matters most is if Denner can get BP interested enough to make a reasonable BO offer.
I wish we knew if the version of Vascepa that is absorbed through the Lymphatic system could be viable
as a patentable product. If such a product is more effective in getting into the brain it could become a focus
point for BP to want to acquire AMRN as it could become an Alzheimer's Disease treatment and be a money
maker for BP. Also, such a product may be more effective as an adjunct treatment for various Cancers...Not
a cure, but as a drug that would result in significantly better outcomes than a cancer treatment or drug than
without it. Regardless, only a BP owning AMRN will ever result in optimizing the uptake of the drug as well as
offering protection of the product. (Hard to believe that the idiot CEO JT did not understand that BP had to own
the company in order for the drug to become a success. Even Adam Feuerstein warned him in an article that
he was now playing on Cardiovascular BP turf! JT was "too thick" to understand, and the shareholders along
with CVD patients pay a high price for is idiocy.) Anyhow, I think if "Brave" shows promise the market will
ignore it, but; hopefully, Alex Denner & BP might be paying very close attention.
I wish we knew if the version of Vascepa that is absorbed through the Lymphatic system could be viable
as a patentable product. If such a product is more effective in getting into the brain it could become a focus
point for BP to want to acquire AMRN as it could become an Alzheimer's Disease treatment and be a money
maker for BP. Also, such a product may be more effective as an adjunct treatment for various Cancers...Not
a cure, but as a drug that would result in significantly better outcomes than a cancer treatment or drug than
without it. Regardless, only a BP owning AMRN will ever result in optimizing the uptake of the drug as well as
offering protection of the product. (Hard to believe that the idiot CEO JT did not understand that BP had to own
the company in order for the drug to become a success. Even Adam Feuerstein warned him in an article that
he was now playing on Cardiovascular BP turf! JT was "too thick" to understand, and the shareholders along
with CVD patients pay a high price for is idiocy.) Anyhow, I think if "Brave" shows promise the market will
ignore it, but; hopefully, Alex Denner & BP might be paying very close attention.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
